Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids

Prostaglandins and Other Lipid Mediators

Volumn 83, Issue 3 SPEC. ISS., 2007, Pages 188-197

  Rubin, Paul ^a   Mollison, Karl W ^a  

^a Critical Therapeutics Inc   (United States)

Author keywords

5 Lipoxygenase; 5 Oxo ETE; Acne; Allergic rhinitis; Asthma; Atherosclerosis; Atopic dermatitis; BLT1; BLT2; COPD; CysLT1; CysLT2; FOG7; Idiopathic pulmonary fibrosis; Ischemia reperfusion; Leukotrienes; Montelukast; OXE; Pranlukast; Zafirlukast; Zileuton

Indexed keywords

5 HYDROXYICOSATETRAENOIC ACID; 5 OXO 6,8,11,14 ICOSATETRAENOIC ACID; 5 OXO 7 GLUTATHIONYL 8,11,14 EICOSATETRAENOIC ACID; ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID DERIVATIVE; CYSTEINYL LEUKOTRIENE 1; CYSTEINYL LEUKOTRIENE 2; GLUCOCORTICOID; ICOSANOID; LEUKOTRIENE B4 RECEPTOR; LEUKOTRIENE B4 RECEPTOR 1; LEUKOTRIENE B4 RECEPTOR 2; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE DERIVATIVE; LEUKOTRIENE E4; LEUKOTRIENE F4; MONTELUKAST; OXOEICOSANOID; PEPTIDOLEUKOTRIENE; PRANLUKAST; UNCLASSIFIED DRUG; ZAFIRLUKAST; ZILEUTON;

ACNE VULGARIS; ALLERGIC RHINITIS; ARACHIDONIC ACID METABOLISM; ARTICLE; ASTHMA; ATHEROSCLEROSIS; ATOPIC DERMATITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFICACY; DRUG INHIBITION; ENZYME ACTIVATION; EXERCISE INDUCED ASTHMA; FIBROSING ALVEOLITIS; HUMAN; INFLAMMATION; ISCHEMIA; NONHUMAN; ORGAN INJURY; REPERFUSION INJURY;

EID: 34247541994     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2007.01.005     Document Type: Article

References (93)

1. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220 (1983) 568-575
2. Brink C., Dahlen S.E., Drazen J., et al. International Union of Pharmacology XLIV. Nomenclature for the oxoeicosanoid receptor. Pharmacol Rev 56 (2004) 149-157
3. Bowers R.C., Hevko J., Henson P.M., and Murphy R.C. A novel glutathione containing eicosanoid (FOG7) chemotactic for human granulocytes. J Biol Chem 275 (2000) 29931-29934
4. Tager A.M., and Luster A.D. BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot Essent Fatty Acids 69 (2003) 123-134
5. 2. J Biol Chem 276 (2001) 12454-12459
6. 4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol 24 (2004) 369-375
7. Fregonese L., Silvestri M., Sabatini F., and Rossi G.A. Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism. Clin Exp Allergy 32 (2002) 745-750
8. Mellor E.A., Austen K.F., and Boyce J.A. Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. J Exp Med 195 (2002) 583-592
9. Mellor E.A., Frank N., Soler D., et al. Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: functional distinction from CysLT1R. Proc Natl Acad Sci USA 100 (2003) 11589-11593
10. Asakura T., Ishii Y., Chibana K., and Fukuda T. Leukotriene D4 stimulates collagen production from myofibroblasts transformed by TGF-beta. J Allergy Clin Immunol 114 (2004) 310-315
11. Beller T.C., Maekawa A., Friend D.S., Austen K.F., and Kanaoka Y. Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. J Biol Chem 279 (2004) 46129-46134
12. Henderson Jr. W.R., Tang L.O., Chu S.J., et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 165 (2002) 108-116
13. Panettieri R.A., Tan E.M.L., Ciocca V., Luttmann M.A., Leonard T.B., and Hay D.W.P. Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction In vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists. Am J Respir Cell Mol Biol 19 (1998) 453-461
14. Leikauf G.D., Claesson H.E., Doupnik C.A., Hybbinette S., and Grafstrom R.C. Cysteinyl leukotrienes enhance growth of human airway epithelial cells. Am J Physiol 259 (1990) L255-L261
15. Sloniewsky D.E., Ridge K.M., Adir Y., et al. Leukotriene D4 activates alveolar epithelial Na,K-ATPase and increases alveolar fluid clearance. Am J Respir Crit Care Med 169 (2004) 407-412
16. Wenzel S.E. The role of leukotrienes in asthma. Prostaglandins Leukot Essent Fatty Acids 69 (2003) 145-155
17. 4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax 51 (1996) 1178-1184
18. Busse W.W., and Lemanske Jr. R.F. Asthma. N Engl J Med 344 (2001) 350-362
19. Ducharme F.M., and Di Salvo F. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 3 (2002) CD002314
20. Barnes P.J. Anti-leukotrienes: here to stay?. Curr Opin Pharmacol 3 (2003) 257-263
21. Hasday J.D., Meltzer S.S., Moore W.C., et al. Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics. Am J Respir Crit Care Med 161 (2000) 1229-1236
22. Jenkins C., Costello J., and Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 328 (2004) 434
23. Kumlin M., Dahlen B., Bjorck T., Zetterstrom O., Granstrom E., and Dahlen S.E. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am Rev Respir Dis 146 (1992) 96-103
24. Stevenson D.D., Simon R.A., Mathison D.A., and Christiansen S.C. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol 85 (2000) 477-482
25. Dahlen B., Nizankowska E., Szczeklik A., et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 157 (1998) 1187-1194
26. Drazen J.M., Israel E., and O'Byrne P.M. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 340 (1999) 197-206
27. Reiss T.F., Hill J.B., Harman E., et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 52 (1997) 1030-1035
28. Leff J.A., Busse W.W., Pearlman D., et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 339 (1998) 147-152
29. Meltzer S.S., Hasday J.D., Cohn J., and Bleecker E.R. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 153 (1996) 931-935
30. Salvi S., Krishna M.T., Sampson A.P., and Holgate S.T. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest 119 (2001) 1533-1546
31. Fahy J.V., Kim K.W., Liu J., and Boushey H.A. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 95 (1995) 843-852
32. Ordonez C.L., Shaughnessy T.E., Mathay M.A., and Fahy J.V. Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: clinical and biologic significance. Am J Respir Crit Care Med 161 (2000) 1185-1190
33. Sur S., Crotty T.B., Kephart G.M., et al. Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa?. Am Rev Respir Dis 148 (1993) 713-719
34. Jatakanon A., Uasuf C., Maziak W., Lim S., Chung K.F., and Barnes P.J. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 160 (1999) 1532-1539
35. 4 mediates histamine induction of NF-kappa B and IL-8 in human bronchial epithelial cells. Am J Physiol 274 (1998) L1030-L1039
36. Wenzel S. Mechanisms of severe asthma. Clin Exp Allergy 33 (2003) 1622-1628
37. 4 by purified human neutrophils. J Pharmacol Exp Ther 250 (1989) 598-605
38. Gelfand E.W. Inflammatory mediators in allergic rhinitis. J Allergy Clin Immunol 114 (2004) S135-S138
39. Riccio A.M., Tosca M.A., Cosentino C., et al. Cytokine pattern in allergic and non-allergic chronic rhinosinusitis in asthmatic children. Clin Exp Allergy 32 (2002) 422-426
40. Figueroa D.G., Borish L., Baramki D., Philip G., Austin C.P., and Evans J.F. Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis. Clin Exp Allergy 33 (2003) 1380-1388
41. Lipworth B.J. Emerging role of antileukotriene therapy in allergic rhinitis. Clin Exp Allergy 31 (2001) 1813-1821
42. Parnes S.M. The role of leukotriene inhibitors in allergic rhinitis and paranasal sinusitis. Curr Allergy Asthma Rep 2 (2002) 239-244
43. Steinke J.W., and Borish L. Leukotriene receptors in rhinitis and sinusitis. Curr Allergy Asthma Rep 4 (2004) 217-223
44. Barnes P.J. Mechanisms in COPD: differences from asthma. Chest 117 Suppl. 2 (2000) 10S-14S
45. Montuschi P., Kharitonov S.A., Ciabattoni G., and Barnes P.J. Exhaled leukotrienes and prostaglandins in COPD. Thorax 58 (2003) 585-588
46. 4. Chest 123 (2003) 1240-1247
47. Perng D.W., Huang H.Y., Chen H.M., Lee Y.C., and Perng R.P. Characteristics of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment. Chest 126 (2004) 375-381
48. Kilfeather S. 5-Lipoxygenase inhibitors for the treatment of COPD. Chest 121 Suppl. 5 (2002) 197S-200S
49. Wilborn J., Bailie M., Coffey M., Burdick M., Strieter R., and Peters-Golden M. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 97 (1996) 1827-1836
50. Peters-Golden M., Bailie M., Marshall T., et al. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 165 (2002) 229-235
51. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
52. Spanbroek R., Grabner R., Lotzer K., et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 100 (2003) 1238-1243
53. Dwyer J.H., Allayee H., Dwyer K.M., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 350 (2004) 29-37
54. Helgadottir A., Manolescu A., Thorleifsson G., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36 (2004) 233-239
55. Mehrabian M., Allayee H., Wong J., et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 91 (2002) 120-126
56. 4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 22 (2002) 443-449
57. Allen S., Dashwood M., Morrison K., and Yacoub M. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 97 (1998) 2406-2413
58. Kamohara M., Takasaki J., Matsumoto M., et al. Functional characterization of cysteinyl leukotriene CysLT(2) receptor on human coronary artery smooth muscle cells. Biochem Biophys Res Commun 287 (2001) 1088-1092
59. Rackal J.M., and Vender R.B. The treatment of atopic dermatitis and other dermatoses with leukotriene antagonists. Skin Therapy Lett 9 (2004) 1-5
60. Leung D.Y.M., Boguniewicz M., Howell M.D., Nomura I., and Hamid Q.A. New insights into atopic dermatitis. J Clin Invest 113 (2004) 651-657
61. 4 from leukocytes of patients with atopic eczema. Acta Derm Venereol 67 (1987) 469-475
62. 4 into peptide leukotrienes: possible role in transcellular metabolism. Arch Dermatol Res 286 (1994) 261-266
63. 4 released by a type I allergic reaction in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 103 (1999) 663-670
64. 4) in human skin. J Invest Dermatol 80 (1983) 115-119
65. Talbot S.F., Atkins P.C., Goetzl E.J., and Zweiman B. Accumulation of leukotriene C4 and histamine in human allergic skin reactions. J Clin Invest 76 (1985) 650-656
66. Reshef A., Kagey-Sobotka A., Adkinson Jr. N.F., Lichtenstein L.M., and Norman P.S. The pattern and kinetics in human skin of erythema and mediators during the acute and late-phase response (LPR). J Allergy Clin Immunol 84 (1989) 678-687
67. Woodmansee D.P., and Simon R.A. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol 83 (1999) 548-552
68. Zouboulis C.C. Exploration of retinoid activity and the role of inflammation in acne: issues affecting future directions for acne therapy. Eur Acad Dermatol Venereol 15 Suppl. 3 (2001) 63-67
69. 4, stimulate DNA synthesis in cultured human epidermal keratinocytes. Br J Dermatol 113 (1985) 43-52
70. 4 hydrolase in human skin. Soc Invest Dermatol 102 (1994) 253-257
71. 4 hydrolase. J Invest Dermatol 100 (1993) 293-329
72. Koreck A., Pivarcsi A., Dobozy A., and Kemeny L. The role of innate immunity in the pathogenesis of acne. Dermatology 206 (2003) 96-105
73. Pawin H., Beylot C., Chivot M., Faure M., et al. Physiopathology of acne vulgaris: recent data, new understanding of the treatments. Eur J Dermatol 14 (2004) 4-12
74. Voorhees J.J. Leukotrienes and other lipoxygenase products in the pathogenesis and therapy of psoriasis and other dermatoses. Arch Dermatol 119 (1983) 541-547
75. Zouboulis C.C., Adler Y.D., Picardo M., and Cunliffe W.J. A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor. Arch Dermatol 139 (2003) 668-670
76. Takamatsu Y., Shimada K., Chijiwa K., et al. Role of leukotrienes on hepatic ischemia/reperfusion injury in rats. J Surg Res 119 (2004) 14-20
77. Eppihimer M.J., Russell J., Anderson D.C., et al. Modulation of P-selectin expression in the postischemic intestinal microvasculature. Am J Physiol. 273 (1997) G1326-G1332
78. Pedersen K.E., Bochner B.S., and Undem B.J. Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a non-CysLT1 receptor-mediated mechanism. J Pharmacol Exp Ther 281 (1997) 655-662
79. Cuzzocrea S., Rossi A., Serraino I., et al. 5-Lipoxygenase knockout mice exhibit a resistance to splanchnic artery occlusion shock. Shock 20 (2003) 230-236
80. 4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J Clin Invest 104 (1999) 309-316
81. Mangino M.J., Mangino J.E., Kotadia B., and Sielczak M. Effects of the 5-lipoxygenase inhibitor A-64077 on intestinal hypothermic organ preservation injury. J Pharmacol Exp Ther 281 (1997) 950-956
82. Patel N.S., Cuzzocrea S., Chatterjee P.K., et al. Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. Mol Pharmacol 66 (2004) 220-227
83. Rao A.M., Hatcher J.F., Kindy M.S., and Dempsey R.J. Arachidonic acid and leukotriene C4: role in transient cerebral ischemia of gerbils. Neurochem Res 24 (1999) 1225-1232
84. Lee C.C., Appleyard R.F., Byrne J.G., and Cohn L.H. Leukotrienes D4 and E4 produced in myocardium impair coronary flow and ventricular function after 2 h of global ischaemia in rat heart. Cardiovasc Res 27 (1993) 770-773
85. Welt K., Fitzl G., and Mark B. Lipoxygenase inhibitor FLM 5011, an effective protectant of myocardial microvessels against ischemia-reperfusion injury? An ultrastructural-morphometric study. Exp Toxicol Pathol 52 (2000) 27-36
86. Hashimoto H., Miyazawa K., Hagiwara M., Miyasaka K., and Nakashima M. Beneficial effects of a new 5-lipoxygenase inhibitor on occlusion- and occlusion-reperfusion-induced myocardial injury. Arzneimittelforschung 40 (1990) 126-129
87. Carry M., Korley V., Willerson J.T., et al. Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 85 (1992) 230-236
88. Haynes Jr. J., and Obiako B. Activated polymorphonuclear cells increase sickle red blood cell retention in lung: role of phospholipids. Am J Physiol Heart Circ Physiol 282 (2002) H122-H130
89. 4 to disease pathophysiology. J Lab Clin Med 139 (2002) 80-89
90. Ibe B.O., Kurantsin-Mills J., Raj J.U., and Lessin L.S. Plasma and urinary leukotrienes in sickle cell disease: possible role in the inflammatory process. Eur J Clin Invest 24 (1994) 57-64
91. Haynes Jr. J., Baliga B.S., Obiako B., Ofori-Acquah S., and Pace B. Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway. Blood 103 (2004) 3945-3950
92. Collin M., Rossi A., Cuzzocrea S., et al. Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. J Leukoc Biol 76 (2004) 961-970
93. Benjamim C.F., Canetti C., Cunha F.Q., Kunkel S.L., and Peters-Golden M. Opposing and hierarchical roles of leukotrienes in local innate immune versus vascular responses in a model of sepsis. J Immunol 174 (2005) 1616-1620